Durhane Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of the Advisory Board for the Canadian Institutes of Health Research Institute of Genetics and the Patient Liaison Forum for the Canadian Drugs and Technologies in Health. Durhane is immediate Past-Chair of the International Alliance of Patient Organizations, and Board Member representing patient interests at DIA International Association. She has a PhD in psychology from McGill University.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020
Explore New Approaches to Developing and Gaining Market Access for Drugs to Treat Rare Diseases
Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers. With a growing consensus that a new drug development model is needed, the question becomes what form should it take? Gain valuable insights to inform your market access strategy by:
- Learning what types of partnerships and funding will be key to the successful development of drugs for rare diseases going forward
- Hearing what impact the increased government funding announced in last fall’s federal budget is having on the pipeline of treatments
- Understanding what new routes to market and commercialization for these medications may be forged to get them to patients safely and expeditiously
Prepare your organization for a new market access model for treatments for rare diseases.